DOW JONES NEWSWIRES
ZymoGenetics Inc. (ZGEN) said an experimental immunotherapy treatment for metastatic melanoma showed "positive survival" results in a mid-stage trial.
The data come in the midst of Bristol-Myers Squibb Co.'s (BMY) $836 million buyout of ZymoGenetics. Chief Executive Lamberto Andreotti has said the acquisition would strengthen its Hepatitis C portfolio.
In the study of 40 patients with advanced melanoma, participants were treated with one of three doses of the drug. The median overall survival rate was 12.4 months, with 53% surviving after a year. Overall response rate was 23% in evaluable patients, and progression-free survival was 4.3 months.
Common adverse effects were fatigue, rash, fever myalgia, anorexia, chills and nausea.
Among ZymoGenetics other products are Recothrom, a drug used in surgeries to prevent blood clotting, and six biologic drug candidates for atopic dermatitis.
ZymoGenetics shares closed Tuesday at $9.75--the buyout price--and were inactive premarket.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; firstname.lastname@example.org